GABAergic drugs in the treatment of epilepsy: Modern or outmoded?

Future Medicinal Chemistry

Volumn 3, Issue 2, 2011, Pages 177-182

  Mula, Marco ^a  

^a University Hospital Maggiore della Carita   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAERGIC RECEPTOR AFFECTING AGENT; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

CATABOLISM; COGNITIVE DEFECT; COMPLEX FORMATION; DEPRESSION; DRUG TARGETING; EPILEPSY; HUMAN; MOOD; NERVE EXCITABILITY; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW;

4-AMINOBUTYRATE TRANSAMINASE; AFFECT; ANTICONVULSANTS; COGNITION; EPILEPSY; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; GAMMA-AMINOBUTYRIC ACID; HUMANS; RECEPTORS, GABA-A;

EID: 79951594371     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.296     Document Type: Review

References (50)

1. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5(7), 553-564 (2004). (Pubitemid 38868551)
2. Holtkamp M, Meierkord H. Anticonvulsant, antiepileptogenic, and antiictogenic pharmacostrategies. Cell. Mol. Life Sci. 64(15), 2023-2041 (2007). (Pubitemid 47094429)
3. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 4(1), 18-61 (2007). (Pubitemid 46107329)
4. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet 367(9516), 1087-1100 (2006).
5. Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J. Child Neurol. 19(Suppl. 1), S25-S38 (2004). (Pubitemid 39480768)
6. Carter CRJ, Kozuska JL, Dunn SMJ. Insights into the structure and pharmacology of GABAA receptors. Future Med. Chem. 2(5), 859-875 (2010).
7. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10(7), 685-692 (2004). (Pubitemid 38937632)
8. Whiting PJ. The GABAA receptor gene family: new targets for therapeutic intervention. Neurochem. Int. 34(5), 387-390 (1999). (Pubitemid 29240635)
9. Farrant M, Nusser Z. Variations on an inhibitory theme. Phasic and tonic activation of GABAA receptors. Nat. Rev. Neurosci. 6(3), 215-229 (2005). (Pubitemid 40342416)
10. Stell BM, Brickley SG, Tang CY, Farrant M, Mody I. Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by d subunit-containing GABAA receptors. Proc. Natl Acad. Sci. USA 100(24), 14439-14444 (2003). (Pubitemid 37499255)
11. Monaghan EP, Navalta LA, Shum L, Ashbrook DW, Lee DA. Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia 38(9), 1026-1031 (1997). (Pubitemid 27382941)
12. Cunningham MO, Dhillon A, Wood SJ, Jones RS. Reciprocal modulation of glutamate and GABA release may underlie the anticonvulsant effect of phenytoin. Neuroscience 95(2), 343-351 (2000).
13. Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 39(11), 2139-2146 (2000). (Pubitemid 30645637)
14. Deckers CL, Hekster YA, Keyser A, Meinardi H, Renier WO. Pharmacotherapy of epilepsy: state of the art and developments. J. Clin. Pharm. Ther. 22(5-6), 309-322 (1997). (Pubitemid 28281430)
15. Mula M. New antiepileptic drugs: molecular targets. Cent. Nerv. Syst. Agents Med. Chem. 9(2), 79-86 (2009).
16. Manning JP, Richards DA, Bowery NG. Pharmacology of absence epilepsy. Trends Pharmacol. Sci. 24(10), 542-549 (2003).
17. Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83(1), 1-43 (2009).
18. Conti F, Minelli A, Melone M. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain Res. Brain Res. Rev. 45(3), 196-212 (2004). (Pubitemid 38802871)
19. Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A. GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res. 1(2), 77-93 (1987). (Pubitemid 18048277)
20. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36(6), 612-626 (1995).
21. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 15(5), 339-350 (2001). (Pubitemid 32487991)
22. Porter RJ. Mechanisms of action of new antiepileptic drugs. Epilepsia 30(Suppl. 1), S29-S34 (1989). (Pubitemid 19239010)
23. Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia 42(Suppl. 3), 8-12 (2001). (Pubitemid 32781374)
24. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43(1), 11-58 (2001). (Pubitemid 32008536)
25. Sarup A, Larsson OM, Schousboe A. GABA transporters and GABA-transaminase as drug targets. Curr. Drug Targets CNS Neurol. Disord. 2(4), 269-277 (2003).
26. Mares P, Slamberova R. Biphasic action of vigabatrin on cortical epileptic after-discharges in rats. Naunyn Schmiedebergs Arch. Pharmacol. 369(3), 305-311 (2004). (Pubitemid 38372936)
27. Wu Y, Wang W, Richerson GB. Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release. J. Neurophysiol. 89(4), 2021-2034 (2003). (Pubitemid 36444256)
28. Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. CNS Drugs 23(2), 121-137 (2009).
29. Stewart SA. The effects of benzodiazepines on cognition. J. Clin. Psychiatry 66(Suppl. 2), 9-13 (2005). (Pubitemid 40343675)
30. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 73(1), 1-52 (2007). (Pubitemid 46091734)
31. Meador KJ, Loring DW, Allen ME et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 41(10), 1537-1540 (1991).
32. Meador KJ, Loring DW, Hulihan JF, Kamin M, Karim R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 60(9), 1483-1488 (2003). (Pubitemid 36554811)
33. Aldenkamp AP, De Krom M, Reijs R. Newer antiepileptic drugs and cognitive issues. Epilepsia 44(Suppl. 4), 21-29 (2003). (Pubitemid 36842173)
34. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf. 30(7), 555-567 (2007). (Pubitemid 47037315)
35. Olajide D, Lader M. Depression following withdrawal from long-term benzodiazepine use: a report of four cases. Psychol. Med. 14(4), 937-940 (1984). (Pubitemid 15221263)
36. Trimble M. Biological Psychiatry (2nd Edition). Wiley, Chichester, UK (1996).
37. Petty F. GABA and mood disorders: a brief review and hypothesis. J. Affect. Disord. 34(4), 275-281 (1995).
38. Rodin EA, Rim CS, Kitano H, Lewis R, Rennick PM. A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients. J. Nerv. Ment. Dis. 163(1), 41-46 (1976).
39. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 27(11), 1023-1028 (1977). (Pubitemid 8230797)
40. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 53(7), 1503-1511 (1999). (Pubitemid 29491945)
41. Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and psychosis. J. Neurol. Neurosurg. Psychiatry 54(5), 435-439 (1991).
42. Ring HA, Crellin R, Kirker S, Eh R. Vigabatrin and depression. J. Neurol. Neurosurg. Psychiatry 56(8), 925-928 (1993). (Pubitemid 23246159)
43. Trimble MR, Schmitz B. Forced Normalization and Alternative Psychoses of Epilepsy. Wrightson Biomedical Publishing Ltd, Petersfield, UK (1998).
44. Thomas L, Trimble M, Schmitz B, Ring H. Vigabatrin and behaviour disorders: a retrospective survey. Epilepsy Res. 25(1), 21-27 (1996). (Pubitemid 26292676)
45. Kuzniecky R, Ho S, Pan J et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 58(3), 368-372 (2002). (Pubitemid 34150909)
46. Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44(5), 659-663 (2003). (Pubitemid 36554633)
47. Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 50(5), 1072-1076 (2009).
48. Mula M, Sander JW, Trimble MR. The role of hippocampal sclerosis in antiepileptic drug-related depression in patients with epilepsy: a study on levetiracetam. Seizure 15(6), 405-408 (2006). (Pubitemid 44184813)
49. Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 44(12), 1573-1577 (2003). (Pubitemid 38020194)
50. Mula M, Trimble MR, Sander JW. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam. Epilepsia 48(12), 2322-2326 (2007). (Pubitemid 350243412)